Company Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
0.8771 ^USD	-5.69%		+20.15%	-25.67%

26/04	Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
26/04	Vincerx Pharma Prices Public Offering of Shares, Warrants	MT

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Number of employees: 42

Managers	Title	Age	Since
Soo In Hwang FOU	Founder	64	19/18/19
Raquel Izumi FOU	Founder	54	19/18/19
Tom Thomas FOU	Founder	64	19/18/19
Ahmed Hamdy CEO	Chief Executive Officer	59	19/18/19
Alexander Seelenberger Farba DFI	Director of Finance/CFO	45	01/20/01
Amy Johnson CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Hans-Georg Lerchen CTO	Chief Tech/Sci/R&D Officer	-	02/21/02
Tasheda Navarro CTO	Chief Tech/Sci/R&D Officer	-	-
Melissa Merrick HRO	Human Resources Officer	-	01/21/01
Bill Donaldson LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Ahmed Hamdy CEO	Chief Executive Officer	59	19/18/19
Laura Bushnell BRD	Director/Board Member	56	23/20/23
Brian Druker BRD	Director/Board Member	68	23/20/23
Ruth Stevens BRD	Director/Board Member	64	01/21/01
John Lee BRD	Director/Board Member	56	23/20/23
Francisco Salva BRD	Director/Board Member	53	23/20/23
Raquel Izumi FOU	Founder	54	19/18/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	23,534,238	22,010,613 ( 93.53 %)	0	93.53 %

Name	Equities	%	Valuation
Lifesci Investments LLC 12.02 %	2,570,000	12.02 %	13 M $
Prosight Management LP 11.68 %	2,497,218	11.68 %	13 M $
Ahmed Hamdy 8.018 %	1,714,259	8.018 %	9 M $
Goldman Sachs & Co. LLC 7.996 %	1,709,656	7.996 %	9 M $
Raquel Izumi 7.972 %	1,704,413	7.972 %	9 M $
Sage Rhino Capital LLC 7.967 %	1,703,413	7.967 %	9 M $
John Byrd 7.569 %	1,618,199	7.569 %	8 M $
Long Focus Capital Management LLC 5.139 %	1,098,753	5.139 %	6 M $
Bank of America, NA (Charlotte, North Carolina) 5.065 %	1,082,863	5.065 %	5 M $
Rock Springs Capital Management LP 4.171 %	891,719	4.171 %	5 M $

Vincerx Pharma, Inc.

260 Sheridan Avenue Suite 400

94306, Palo Alto

http://www.vincerapharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8771 USD

Average target price

9 USD

Spread / Average Target

+926.11%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VINCERX PHARMA, INC.	-25.67%	25.9M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs